Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von JPMorgan Chase & Co. 

AnaptysBio Inc diskutieren

AnaptysBio Inc

WKN: A2AJ8C / Symbol: ANAB / Name: AnaptysBio / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

44,94 €
-1,01 %

Einschätzung Buy
Rendite (%) 56,04 %
Kursziel 60,59
Veränderung
Endet am 11.11.26

AnaptysBio (NASDAQ:ANAB) was given a new $70.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 19,29 %
Kursziel 43,44
Veränderung
Endet am 24.11.26

AnaptysBio (NASDAQ:ANAB) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $50.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 19,29 %
Kursziel 44,30
Veränderung
Endet am 24.11.26

AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) 15,82 %
Kursziel 47,91
Veränderung
Endet am 11.12.26

AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat

AnaptysBio (NASDAQ:ANAB) had its "buy" rating reaffirmed by analysts at Guggenheim.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,92 %
Kursziel 56,91
Veränderung
Endet am 04.03.27

AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -13,92 %
Kursziel 68,11
Veränderung
Endet am 04.03.27

AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -15,58 %
Kursziel 73,13
Veränderung
Endet am 05.03.27

AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -18,29 %
Kursziel 65,03
Veränderung
Endet am 12.03.27

AnaptysBio (ANAB) had its price target raised by Wedbush from $60.00 to $75.00. They now have an "outperform" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -24,31 %
Kursziel 78,28
Veränderung
Endet am 17.03.27

AnaptysBio (ANAB) had its price target raised by UBS Group AG from $70.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -10,77 %
Kursziel 57,31
Veränderung
Endet am 30.03.27

AnaptysBio (ANAB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $66.00 price target on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -8,54 %
Kursziel 82,76
Veränderung
Endet am 31.03.27

AnaptysBio (ANAB) had its price target raised by Piper Sandler from $67.00 to $95.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,34 %
Kursziel 53,64
Veränderung
Endet am 22.04.27

AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.
Ratings data for ANAB provided by MarketBeat